CeriBell (NASDAQ:CBLL) Releases Earnings Results, Beats Estimates By $0.07 EPS

CeriBell (NASDAQ:CBLL) announced its earnings results on Tuesday. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07, FiscalAI reports. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The business had revenue of $24.78 million for the quarter, compared to analyst estimates of $23.95 million.

Here are the key takeaways from CeriBell’s conference call:

• Strong top-line growth and solid cash runway — Q4 revenue was $24.8M (+34% YoY) and full-year 2025 revenue was $89.1M (+36%); management guides 2026 revenue of $111M–$115M and ended 2025 with $159M in cash and marketable securities.
• Regulatory and access wins materially expand addressable market — FedRAMP High approval (opens VA system), FDA 510(k) clears for neonatal/pediatric seizure detection, FDA clearance for delirium algorithm, and Breakthrough Device designation for inpatient LVO stroke; management now estimates TAM ≈ $3.5B.
• Commercial traction with room to scale — 647 active hospital accounts (118 net adds in 2025), expansion from ~35 to ~55 territories, and a playbook to drive deeper utilization (currently ~30% penetration) plus a new system-level sales focus expected to accelerate account adds in 2H 2026–2027.
• Rising operating expenses, litigation and margin pressure — FY operating expenses rose 42% to $136.7M and net loss was $53.4M; management expects elevated OpEx (R&D, IP litigation) and mid-80% gross margins in 2026 due to tariff-related cost shifts.
• New product timing limits near-term revenue impact — Neonatal/pediatric full commercial launch targeted for Q2 2026 with modest 2026 contribution (material revenue expected in 2027+); delirium pilots and NTAP pursuit could drive upside but are expected to scale later in 2026–2027.

CeriBell Stock Performance

CBLL stock traded down $0.09 during trading hours on Tuesday, reaching $19.90. The stock had a trading volume of 268,811 shares, compared to its average volume of 341,264. The stock has a 50-day simple moving average of $21.30 and a 200 day simple moving average of $16.12. CeriBell has a fifty-two week low of $10.01 and a fifty-two week high of $26.04. The stock has a market capitalization of $738.21 million, a PE ratio of -13.18 and a beta of 1.03. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25.

Analyst Upgrades and Downgrades

CBLL has been the topic of a number of research reports. JPMorgan Chase & Co. cut their price objective on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. BTIG Research reiterated a “buy” rating and issued a $30.00 price target on shares of CeriBell in a research note on Wednesday, January 28th. TD Cowen reissued a “buy” rating on shares of CeriBell in a research report on Tuesday, December 9th. Finally, Canaccord Genuity Group raised their price objective on CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $24.67.

Insider Buying and Selling

In related news, CTO Raymond Woo sold 11,112 shares of CeriBell stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $21.18, for a total transaction of $235,352.16. Following the completion of the transaction, the chief technology officer owned 167,317 shares in the company, valued at approximately $3,543,774.06. This trade represents a 6.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP David Foehr sold 5,556 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $20.00, for a total value of $111,120.00. Following the completion of the sale, the vice president owned 18,900 shares in the company, valued at $378,000. This represents a 22.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 336,370 shares of company stock worth $6,863,908 in the last 90 days. 20.10% of the stock is owned by corporate insiders.

Institutional Trading of CeriBell

Large investors have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its holdings in CeriBell by 6,424.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock worth $7,117,000 after purchasing an additional 374,179 shares during the last quarter. Rhumbline Advisers increased its position in shares of CeriBell by 109.9% during the second quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock worth $614,000 after buying an additional 17,177 shares during the period. New York State Common Retirement Fund raised its stake in CeriBell by 148.6% during the second quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock worth $163,000 after buying an additional 5,200 shares during the last quarter. Quantbot Technologies LP lifted its holdings in CeriBell by 70.3% in the second quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock valued at $290,000 after buying an additional 6,401 shares during the period. Finally, Invesco Ltd. bought a new stake in CeriBell during the second quarter valued at $197,000.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.